A5030303296- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Bone health and treatments
- Breast Cancer Treatment Studies
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Estrogen and related hormone effects
- Cancer Risks and Factors
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Management of metastatic bone disease
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Reproductive Biology and Fertility
- Chronic Lymphocytic Leukemia Research
- Cancer-related cognitive impairment studies
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Prostate Cancer Treatment and Research
- Economic and Financial Impacts of Cancer
- Cancer, Lipids, and Metabolism
- Metabolism, Diabetes, and Cancer
- Telemedicine and Telehealth Implementation
Dana-Farber Cancer Institute
2015-2024
Champalimaud Foundation
2019-2024
Universidade Católica Portuguesa
2022-2024
Hospital Braga
2013-2024
Hospital de Santa Maria
2013-2021
University of Lisbon
2006-2021
Institut Gustave Roussy
2019-2021
Institut Jules Bordet
2017-2020
Université Libre de Bruxelles
2018-2020
Inserm
2019-2020
Nonadherence to long-term treatments is often under-recognized by physicians and there no gold standard for its assessment. In breast cancer, nonadherence tamoxifen therapy after surgery constitutes a major obstacle optimal outcomes. We sought evaluate the rate of biochemical adjuvant using serum assessment examine effects on short-term, distant disease-free survival (DDFS).We studied 1,177 premenopausal women enrolled in large prospective study (CANTO/NCT01993498). Definition was based...
Abstract The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome remains uncertain. Here we present final results a phase Ib/IIa, open-label trial (NCT02871791) exemestane plus everolimus palbociclib for CDK4/6i-resistant metastatic breast cancer. primary objective Ib was evaluate safety tolerability determine maximum tolerated dose/recommended II dose (100 mg palbociclib, 5 everolimus, 25...
Introduction: Innovations in 3D spatial technology and augmented reality imaging driven by digital high-tech industrial science have accelerated experimental advances breast cancer the development of medical procedures aimed to reduce invasiveness. Presentation case: A 57-year-old post-menopausal woman presented with screen-detected left-sided cancer. After undergoing all staging pre-operative studies patient was proposed for conservative surgery tumor localization. During surgery, an...
PURPOSE Socioeconomic status (SES) influences the survival outcomes of patients with early breast cancer (EBC). However, limited research investigates social inequalities in their quality life (QoL). This study examines socioeconomic QoL after an EBC diagnosis and time trends. PATIENTS AND METHODS We used data from French prospective multicentric CANTO cohort (ClinicalTrials.gov identifier: NCT01993498 ), including women enrolled between 2012 2018. was assessed using European Organisation...
Abstract Background The diagnosis of mixed invasive ductal and lobular carcinoma (IDC-L) in clinical practice is often associated with uncertainty related to its prognosis response systemic therapies. With the increasing recognition (ILC) as a distinct disease subtype, questions surrounding IDC-L become even more relevant. In this study, we took advantage detailed database compare ILC regarding clinicopathologic treatment characteristics, prognostic power histologic grade, survival outcomes....
Abstract Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant ( mBRCA ) have similar outcomes as non-carriers. However, the impact of type gene BRCA1 vs. BRCA2 and hormone receptor status (positive [HR+] negative [HR−]) on clinical behavior BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study that included diagnosed, between January 2000 December 2012, with stage I–III invasive early at age ≤40 years. From 30...
BackgroundRemote patient monitoring (RPM) of symptoms using electronic reported outcomes (ePROs) has been shown to reduce symptom burden and hospitalizations, increase dose intensity improve quality life patients during systemic therapy being recommended by international guidelines in routine oncology practice. However, implementation care slow faces several challenges. In this study we report on the real-world multi-center a RPM pathway encompassing weekly ePRO reporting with alert...
The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as potential therapeutic target. In this study, the authors aimed to assess impact of serum FGF23 levels prognosis patients with cancer bone metastases from solid tumors. A cohort 112 metastatic disease were treated bone-targeted agents (BTA). Serum baseline was quantified by ELISA dichotomized FGF23high FGF23low groups. Additionally, association between overall survival (OS) time...
Abstract Background. We evaluated the patterns of care and clinical outcomes metastatic breast cancer patients treated with first-line trastuzumab-based therapy after previous (neo)adjuvant trastuzumab. Materials Methods. A total 416 consecutive, HER2-positive who had received were identified at 14 Italian centers. 113 presented de novo stage IV disease analyzed separately. Dichotomous using logistic regression time-to-event Cox proportional hazards models. Results. In 202 trastuzumab-naïve...
YB-1 (Y-box binding protein 1) is a multifunctional cold-shock that has been implicated in all hallmarks of cancer. Elevated level was associated with poor prognosis several types cancers, including breast cancer (BC), where it marker decreased overall survival (OS) and distant metastasis-free across subtypes. also secreted by different cell may act as an extracellular mitogen; however the pathological implications form (sYB-1) are unknown. Our purpose to retrospectively evaluate association...
BackgroundEvidence on how weight loss correlates to health-related quality-of-life (HRQOL) among obese breast cancer (BC) patients is limited. We aimed evaluate associations between changes and HRQOL.MethodsWe included 993 women with stage I-II-III BC from CANTO, a multicenter, prospective cohort collecting longitudinal, objectively-assessed anthropometric measures HRQOL data (NCT01993498). Associations (±5% diagnosis post-treatment [shortly after completion of surgery, adjuvant chemo- or...
Real-world (RW) data may provide valuable information on the effectiveness and safety of medicines, which is particularly relevant for clinicians, patients third-party payers. Evidence palbociclib plus fulvestrant scarce, highlights need additional studies. The aim this study was to evaluate in advanced breast cancer (ABC).We conducted a population-based retrospective cohort cases interest were identified through Portuguese National Cancer Registry database sources. Patients aged≥18 years,...